ZANTAC 150
LOE ApproachingNDAORALTABLET
Approved
Jun 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC 150 is an oral tablet small molecule approved in 1983 for gastrointestinal indications. The specific mechanism of action and therapeutic indications are not documented in available data. This is a mature, legacy product in the GSK portfolio with long-established clinical utility.
LOE Approaching
Product faces approaching loss of exclusivity with moderate competitive pressure (30/100); team size and investment likely stable but transitioning to defense and generic support strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers
Started May 2009
42 enrolled
Healthy
Career Relevance
ZANTAC 150 is a legacy product with minimal linked job openings, reflecting its mature lifecycle stage. Roles available are primarily defensive, focused on market share protection, generic competition management, and cost optimization rather than growth or innovation.
Brand Manager
Worked on ZANTAC 150 at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.